在患有gBRCA-m上皮卵巢癌的患者中,化疗诱导的骨髓抑制:一项回顾性研究
Hongtao Hu1, Xianglin Nie1, Yuxin Jiang1
1Department of Gynaecology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu, China.
Cancer medicine
|March 13, 2026
概括
在上皮卵巢癌 (EOC) 患者中,生殖系BRCA突变 (gBRCA-m) 会导致早期和更严重的化疗诱导骨髓抑制 (CIM). 这需要对这些人进行更密切的监测和个性化治疗策略.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 生殖线BRCA突变 (gBRCA-m) 与上皮卵巢癌 (EOC) 的化疗敏感性和毒性增加有关.
- 在EOC患者中,gBRCA-m对化疗诱导骨髓抑制 (CIM) 的特定影响仍然不完全理解.
研究的目的:
- 研究gBRCA-m对接受一线化疗的EOC患者中CIM发生率和严重性的影响.
- 为了比较带有gBRCA-m和没有gBRCA-m的EOC患者之间的CIM结果.
主要方法:
- 从242名EOC患者 (2018年1月至2023年8月) 的化疗方案和骨髓抑制数据的回顾性审查.
- 将患者分为gBRCA-m (27%) 和gBRCA野生型组.
- 多变量分析以评估gBRCA-m和CIM发病率/严重程度之间的关联.
主要成果:
- 患有gBRCA-m的患者经历了显著较早的发病和最严重的骨髓抑制 (p < 0.001).
- 携带gBRCA-m的携带者更有可能发生第四级骨髓抑制 (aOR=5.585) 和更明显的血细胞计数和血红蛋白降低.
- 在gBRCA-m患者中观察到化学疗法剂量减少 (aOR=2.606) 和延迟 (aOR=4.118) 的风险增加.
结论:
- 带有gBRCA-m的EOC患者表现出早期和更严重的化疗诱导的骨髓抑制.
- 这些发现强调了在gBRCA-m EOC患者中对CIM的警监测的重要性.
- 量身定制的管理策略对于优化这种患者亚组的治疗结果至关重要.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
763
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
763
Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
715
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
715
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
1.0K
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
1.0K
Cancer Therapies
10.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K


